Most major donation organizations, including the American Red Cross, do not list these medications as grounds for deferral, provided your underlying health conditions are well-managed and you are not experiencing significant side effects
Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients
Moreover, the reduction in appetite and changes in food preferences towards lower-fat options contribute to a healthier diet, further supporting overall health
placebo preserved 5.5% additional weight loss at 88 weeks Typical taper window / 8 to 16 weeks of stepwise dose reduction before full stop Switching GLP-1s / direct substitution on the same injection day is generally well tolerated per clinical practice guidelines Long-term therapy indication / AACE guidelines classify obesity as a chronic disease requiring ongoing treatment Cardiovascular benefit / SELECT trial showed 20% MACE reduction with semaglutide 2.4 mg over 34.2 months Why stopping a GLP-1 abruptly almost always triggers weight regain Abrupt discontinuation of a GLP-1 receptor agonist removes a pharmacological brake on appetite, gastric emptying, and reward-pathway signaling all at once
It also has evidenced weight loss benefits in non-diabetic individuals with obesity [6]
/assets/images/provider/photos/2802570.png)
